Sanguine Corporation Completes the Formation of Life Sciences Subsidiary

PASADENA, Calif.--(Business Wire)--
Sanguine Corporation (OTCBB:SGNC) is pleased to announce the
forming of Sanguine Life Sciences, a fully owned subsidiary of
Sanguine Corporation. The Company's product, PHER-O2, is considered to
be an oxygen carrier. The Life Sciences division will focus on the
development of PHER-O2 as an oxygen-carrying synthetic substitute for
human red blood cells and various other areas requiring oxygen
profusion. PHER-O2 consists of perfluoro-decalin molecules, purified
water, and a proprietary synthetic - patent pending fluorinated
surfactant to hold the emulsion together. Additional bio-technology
products and/or future biotechnical acquisitions are planned for
inclusion in the Life Sciences division.

According to Sanguine's executive, Mr. David Nelson, "We expect
PHER-O2 to be an integral part of the Company's future once the 510(k)
approval is complete. Our medical advisory team recognizes that there
are numerous intravenous and ex-vivo applications well suited for
PHER-O2, however we feel the Company has a unique opportunity when
considering acquisitions which are both biotechnical and
non-biotechnical related. It is our goal to build a company with gross
revenues and net earnings as well as personnel with regulatory affairs
experience. This was the primary reason for forming the Life Sciences
subsidiary. Management is excited about the significant market for
PHER-O2; however, we feel the Sanguine Corporation can evolve into a
much larger organization. We look forward to being able to announce
more about the growth of the Company in the near future."

Nelson added, "Development work with PHER-O2 related to
intravenous usage continues in Europe. The group conducting the
development had previously used a product, which was developed in
Russia to mirror PHER-O2's predecessor, Fluosol DA; however, they
determined the Russian product variances were too excessive. This
prompted the use of PHER-O2. From what we understand, experiments are
proceeding well with expected results. Further, we have been contacted
by several additional domestic and international entities desirous of
developing experiments using PHER-O2 intravenously. We expect to
proceed with these projects as well as furthering conversations
related to the Company's interest in licensing PHER-O2 as a transport
medium for transplantable tissue."

For information related to the Sanguine Corporation, contact
Investor Relations: Michael Dancy, 801-746-3570, email:
medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including without
limitation, continued acceptance of the Company's products, increased
levels of competition for the Company, new products and technological
changes, the Company's dependence on third-party suppliers, and other
risks detailed from time to time in the Company's periodic reports
filed with the Securities and Exchange Commission.

For Sanguine Corporation
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net

Copyright Business Wire 2008